Profile data is unavailable for this security.
About the company
Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
- Revenue in USD (TTM)65.38m
- Net income in USD-94.37m
- Incorporated2004
- Employees81.00
- LocationMesoblast LtdL 38 55 Collins StMELBOURNE 3000AustraliaAUS
- Phone+61 39639-6036
- Fax+61 39639-6030
- Websitehttps://www.mesoblast.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tyra Biosciences Inc | 0.00 | -111.68m | 1.74bn | 60.00 | -- | 6.18 | -- | -- | -1.88 | -1.88 | 0.00 | 5.26 | 0.00 | -- | -- | 0.00 | -32.73 | -24.74 | -34.14 | -25.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -25.09 | -- | 101.48 | -- |
| Zymeworks Inc | 134.48m | -63.43m | 1.74bn | 263.00 | -- | 5.51 | -- | 12.97 | -0.8448 | -0.8448 | 1.78 | 4.23 | 0.3041 | -- | 5.07 | 480,289.30 | -14.34 | -19.80 | -16.73 | -23.38 | -- | -- | -47.16 | -80.81 | -- | -- | 0.00 | -- | 0.3842 | 20.90 | -3.39 | -- | -26.07 | -- |
| Relay Therapeutics Inc | 15.36m | -276.48m | 1.75bn | 192.00 | -- | 3.00 | -- | 113.94 | -1.61 | -1.61 | 0.0895 | 3.26 | 0.0206 | -- | -- | 79,979.16 | -37.05 | -35.52 | -39.04 | -37.06 | -- | -- | -1,800.46 | -2,911.42 | -- | -- | 0.00 | -- | 53.44 | -28.58 | 18.13 | -- | -26.65 | -- |
| Enliven Therapeutics Inc | 0.00 | -97.21m | 1.75bn | 65.00 | -- | 3.67 | -- | -- | -1.85 | -1.85 | 0.00 | 8.03 | 0.00 | -- | -- | 0.00 | -24.41 | -35.02 | -25.43 | -38.16 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.36 | -- | -20.66 | -- |
| Pharvaris NV | 0.00 | -191.34m | 1.79bn | 108.00 | -- | 4.98 | -- | -- | -3.41 | -3.41 | 0.00 | 5.62 | 0.00 | -- | -- | 0.00 | -50.22 | -36.71 | -53.72 | -38.87 | -- | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -33.06 | -- | 109.04 | -- |
| Galecto Inc | 0.00 | -15.84m | 1.81bn | 5.00 | -- | 5.98 | -- | -- | -12.01 | -12.01 | 0.00 | 6.03 | 0.00 | -- | -- | 0.00 | -92.89 | -47.05 | -109.09 | -50.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 44.10 | -- | -- | -- |
| Intellia Therapeutics Inc | 67.67m | -412.69m | 1.82bn | 377.00 | -- | 2.67 | -- | 26.95 | -3.83 | -3.83 | 0.6246 | 5.77 | 0.0666 | -- | 7.53 | 179,498.70 | -40.60 | -35.53 | -45.39 | -39.16 | -- | -- | -609.85 | -872.47 | -- | -- | 0.00 | -- | 16.92 | 3.13 | 20.49 | -- | -20.63 | -- |
| Semnur Pharmaceuticals Inc | 0.00 | -1.46m | 1.84bn | -- | -- | -- | -- | -- | -0.4678 | -0.4678 | 0.00 | -4.05 | 0.00 | -- | -- | -- | -5.54 | -- | -7.67 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -126.45 | -- | -- | -- |
| Nektar Therapeutics | 62.60m | -120.74m | 1.87bn | 61.00 | -- | 15.79 | -- | 29.80 | -7.93 | -7.93 | 4.10 | 4.33 | 0.2055 | -- | 97.13 | 1,026,230.00 | -37.21 | -35.30 | -47.69 | -39.56 | 87.26 | 75.63 | -181.08 | -323.39 | -- | -8.54 | 0.469 | -- | 9.22 | -3.00 | 56.91 | -- | -43.84 | -- |
| Olema Pharmaceuticals Inc | 0.00 | -149.96m | 1.89bn | 122.00 | -- | 5.36 | -- | -- | -1.81 | -1.81 | 0.00 | 4.48 | 0.00 | -- | -- | 0.00 | -51.48 | -31.26 | -58.78 | -33.05 | -- | -- | -- | -- | -- | -- | 0.0097 | -- | -- | -- | -33.95 | -- | -- | -- |
| Mesoblast Ltd (ADR) | 65.38m | -94.37m | 1.90bn | 81.00 | -- | 3.25 | -- | 29.06 | -0.7365 | -0.7365 | 0.5098 | 4.46 | 0.0911 | 1.20 | 2.95 | 807,209.90 | -13.15 | -13.19 | -15.28 | -14.68 | 57.98 | -132.14 | -144.33 | -957.40 | 1.41 | -4.74 | 0.1904 | -- | 191.39 | -11.76 | -16.13 | -- | -20.16 | -- |
| Recursion Pharmaceuticals Inc | 74.68m | -644.76m | 1.91bn | 600.00 | -- | 1.69 | -- | 25.64 | -1.48 | -1.48 | 0.167 | 2.14 | 0.0511 | -- | 2.02 | 124,468.30 | -44.12 | -43.31 | -49.84 | -49.18 | 4.99 | -- | -863.35 | -816.44 | -- | -- | 0.0162 | -- | 26.92 | 79.91 | -39.06 | -- | 2.10 | -- |
| Syndax Pharmaceuticals Inc | 172.60m | -285.42m | 1.95bn | 298.00 | -- | 29.94 | -- | 11.31 | -3.30 | -3.30 | 2.00 | 0.7394 | 0.2752 | 0.4209 | 7.57 | 579,191.30 | -45.50 | -34.74 | -55.38 | -38.78 | 95.96 | -- | -165.37 | -279.37 | 4.12 | -24.68 | 0.8418 | -- | 627.84 | 157.68 | 10.46 | -- | -- | -- |
| Celldex Therapeutics Inc | 1.55m | -258.76m | 2.00bn | 198.00 | -- | 3.79 | -- | 1,291.71 | -3.90 | -3.90 | 0.0233 | 7.92 | 0.0023 | -- | 1.14 | 7,808.08 | -37.63 | -30.06 | -40.28 | -31.85 | -- | -- | -16,737.19 | -3,299.27 | -- | -- | 0.00 | -- | -77.99 | -26.93 | -63.91 | -- | 11.83 | -- |
| Nuvation Bio Inc | 26.75m | -217.48m | 2.00bn | 291.00 | -- | 6.14 | -- | 74.85 | -0.6399 | -0.6399 | 0.0787 | 0.9508 | 0.0456 | -- | 6.34 | 121,581.80 | -37.08 | -33.42 | -41.58 | -34.49 | 54.26 | -- | -813.07 | -11,132.31 | 8.39 | -- | 0.3842 | -- | -- | -- | -649.24 | -- | -24.47 | -- |
| Soleno Therapeutics Inc | 190.41m | 20.48m | 2.02bn | 182.00 | 252.70 | 4.54 | 88.03 | 10.59 | 0.1546 | 0.1546 | 3.61 | 8.61 | 0.4256 | -- | -- | 1,046,181.00 | 4.67 | -28.03 | 5.13 | -30.82 | 98.58 | -- | 10.97 | -130.73 | 5.55 | -- | 0.0997 | -- | -- | -- | 111.64 | -- | 59.83 | -- |
Data as of Mar 03 2026. Currency figures normalised to Mesoblast Ltd's reporting currency: US Dollar USD
2.47%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Legal & General Investment Management Ltd.as of 31 Dec 2025 | 679.02k | 0.53% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 502.35k | 0.39% |
| Susquehanna Financial Group LLLPas of 31 Dec 2025 | 429.84k | 0.33% |
| Morgan Stanley & Co. International Plcas of 31 Dec 2025 | 413.50k | 0.32% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2025 | 395.85k | 0.31% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 171.76k | 0.13% |
| Jane Street Capital LLCas of 31 Dec 2025 | 167.38k | 0.13% |
| Arax Advisory Partnersas of 31 Dec 2025 | 166.48k | 0.13% |
| Aperio Group LLCas of 31 Dec 2025 | 140.51k | 0.11% |
| Citadel Securities LLCas of 31 Dec 2025 | 122.87k | 0.10% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
